Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$275.39+8.32 (+3.12%)
Close on Nov 13, 2026Market cap $17.07BP/E 22.4Yield –
Ascendis Pharma A/S r&d expenses
Research and development expenses are spending on new products and technology.
Ascendis Pharma A/S's R&D Expenses for the twelve months ending Jun 30, 2026 was €279.96M, down 10.1% year over year. For fiscal 2025 it was €303.62M, down 1.1% from the year before. Over ten years it grew 22.3% a year on average. The highest annual figure on record is €413.45M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €303.62M | -1.1% |
| FY2024 | Dec 31, 2024 | €307.00M | -25.7% |
| FY2023 | Dec 31, 2023 | €413.45M | +8.9% |
| FY2022 | Dec 31, 2022 | €379.62M | +28.3% |
| FY2021 | Dec 31, 2021 | €295.87M | +13.4% |
| FY2020 | Dec 31, 2020 | €260.90M | +36.2% |
| FY2019 | Dec 31, 2019 | €191.62M | +36.6% |
| FY2018 | Dec 31, 2018 | €140.28M | +40.9% |
| FY2017 | Dec 31, 2017 | €99.59M | +50.8% |
| FY2016 | Dec 31, 2016 | €66.02M | +62.9% |
| FY2015 | Dec 31, 2015 | €40.53M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €75.89M | +5.4% |
| Q1 FY2026 | Mar 31, 2026 | €59.04M | -31.8% |
| Q4 FY2025 | Dec 31, 2025 | €78.15M | -1.4% |
| Q3 FY2025 | Sep 30, 2025 | €66.88M | -9.1% |
| Q2 FY2025 | Jun 30, 2025 | €71.99M | -13.8% |
| Q1 FY2025 | Mar 31, 2025 | €86.60M | +22.5% |
| Q4 FY2024 | Dec 31, 2024 | €79.30M | -12.7% |
| Q3 FY2024 | Sep 30, 2024 | €73.54M | -34.0% |
| Q2 FY2024 | Jun 30, 2024 | €83.48M | -20.5% |
| Q1 FY2024 | Mar 31, 2024 | €70.69M | -33.4% |
| Q4 FY2023 | Dec 31, 2023 | €90.88M | -16.3% |
| Q3 FY2023 | Sep 30, 2023 | €111.44M | +14.4% |
| Q2 FY2023 | Jun 30, 2023 | €105.02M | +16.2% |
| Q1 FY2023 | Mar 31, 2023 | €106.11M | +27.6% |
| Q4 FY2022 | Dec 31, 2022 | €108.62M | +65.4% |
| Q3 FY2022 | Sep 30, 2022 | €97.43M | +65.8% |
| Q2 FY2022 | Jun 30, 2022 | €90.38M | +8.5% |
| Q1 FY2022 | Mar 31, 2022 | €83.19M | -5.6% |
| Q4 FY2021 | Dec 31, 2021 | €65.65M | -13.3% |
| Q3 FY2021 | Sep 30, 2021 | €58.76M | -8.3% |
| Q2 FY2021 | Jun 30, 2021 | €83.31M | +31.0% |
| Q1 FY2021 | Mar 31, 2021 | €88.15M | +53.3% |
| Q4 FY2020 | Dec 31, 2020 | €75.75M | +50.7% |
| Q3 FY2020 | Sep 30, 2020 | €64.06M | +38.5% |
| Q2 FY2020 | Jun 30, 2020 | €63.58M | +45.1% |
| Q1 FY2020 | Mar 31, 2020 | €57.52M | +12.2% |
| Q4 FY2019 | Dec 31, 2019 | €50.28M | +32.3% |
| Q3 FY2019 | Sep 30, 2019 | €46.26M | +46.8% |
| Q2 FY2019 | Jun 30, 2019 | €43.83M | +8.9% |
| Q1 FY2019 | Mar 31, 2019 | €51.26M | +67.8% |
| Q4 FY2018 | Dec 31, 2018 | €38.00M | +35.5% |
| Q3 FY2018 | Sep 30, 2018 | €31.51M | +8.4% |
| Q2 FY2018 | Jun 30, 2018 | €40.24M | +83.9% |
| Q1 FY2018 | Mar 31, 2018 | €30.54M | +48.2% |
| Q4 FY2017 | Dec 31, 2017 | €28.03M | – |
| Q3 FY2017 | Sep 30, 2017 | €29.07M | – |
| Q2 FY2017 | Jun 30, 2017 | €21.88M | – |
| Q1 FY2017 | Mar 31, 2017 | €20.61M | – |
See a number that looks wrong?